gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diagnostic agents, gadolinium derivatives 4494 131410-48-5

Description:

MoleculeDescription

Synonyms:

  • omniscan
  • gadodiamide
for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions
  • Molecular weight: 573.66
  • Formula: C16H26GdN5O8
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.79 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.46 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 8, 1993 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2398.23 50.11 350 2831 3758 90621508
Skin induration 438.50 50.11 79 3102 3183 90622083
Skin hypertrophy 436.97 50.11 80 3101 3530 90621736
Skin tightness 333.34 50.11 66 3115 4422 90620844
Skin fibrosis 232.28 50.11 38 3143 850 90624416
Fibrosis 197.29 50.11 45 3136 5907 90619359
Skin hyperpigmentation 165.05 50.11 40 3141 6811 90618455
Joint contracture 144.06 50.11 28 3153 1694 90623572
Scar 111.71 50.11 35 3146 15360 90609906
Emotional distress 105.94 50.11 42 3139 36620 90588646
Skin discolouration 98.24 50.11 42 3139 44273 90580993
Anhedonia 87.16 50.11 27 3154 11404 90613862
Peau d'orange 82.90 50.11 12 3169 114 90625152
Erythema 79.36 50.11 65 3116 229181 90396085
Joint range of motion decreased 77.44 50.11 52 3129 135591 90489675
Oedema peripheral 74.68 50.11 66 3115 257849 90367417
Extremity contracture 72.09 50.11 15 3166 1278 90623988
Muscle contracture 66.97 50.11 15 3166 1806 90623460
Skin plaque 65.39 50.11 21 3160 9954 90615312
Deformity 65.22 50.11 22 3159 12148 90613118
Pain 62.83 50.11 119 3062 996222 89629044
Joint stiffness 59.64 50.11 36 3145 78006 90547260
Contrast media deposition 57.19 50.11 8 3173 58 90625208
Magnetic resonance imaging head abnormal 56.82 50.11 14 3167 2542 90622724

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 2468.56 48.17 389 2865 3112 42614969
Skin hypertrophy 389.56 48.17 79 3175 2710 42615371
Skin induration 381.08 48.17 73 3181 1854 42616227
Skin tightness 377.20 48.17 74 3180 2136 42615945
Joint range of motion decreased 246.38 48.17 66 3188 7687 42610394
Joint contracture 241.52 48.17 51 3203 2130 42615951
Skin fibrosis 232.05 48.17 43 3211 904 42617177
Fibrosis 182.19 48.17 43 3211 2987 42615094
Scar 170.94 48.17 48 3206 6640 42611441
Extremity contracture 138.19 48.17 27 3227 757 42617324
Deformity 135.33 48.17 30 3224 1572 42616509
Emotional distress 133.19 48.17 49 3205 16044 42602037
Mobility decreased 123.16 48.17 58 3196 35248 42582833
Joint stiffness 114.95 48.17 41 3213 12281 42605800
Anhedonia 113.19 48.17 36 3218 7604 42610477
Oedema peripheral 88.31 48.17 77 3177 135999 42482082
Injury 88.17 48.17 40 3214 22276 42595805
Pain 85.73 48.17 99 3155 244749 42373332
Skin disorder 68.90 48.17 31 3223 16913 42601168
Skin discolouration 68.73 48.17 33 3221 20857 42597224
Musculoskeletal stiffness 64.19 48.17 45 3209 57720 42560361
Skin hyperpigmentation 63.13 48.17 20 3234 4161 42613920
Anxiety 53.62 48.17 55 3199 118505 42499576
Peau d'orange 53.57 48.17 9 3245 104 42617977
Gait inability 51.59 48.17 28 3226 22805 42595276
Muscle contracture 49.23 48.17 13 3241 1422 42616659

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nephrogenic systemic fibrosis 3372.25 48.16 505 4468 4978 110579348
Skin hypertrophy 653.06 48.16 123 4850 4924 110579402
Skin induration 631.45 48.16 117 4856 4278 110580048
Skin tightness 566.07 48.16 111 4862 5502 110578824
Skin fibrosis 365.78 48.16 62 4911 1338 110582988
Joint contracture 304.93 48.16 58 4915 2433 110581893
Fibrosis 240.14 48.16 58 4915 7584 110576742
Scar 207.70 48.16 61 4912 16820 110567506
Biopsy brain abnormal 182.47 48.16 21 4952 8 110584318
Skin hyperpigmentation 178.70 48.16 47 4926 8649 110575677
Joint range of motion decreased 173.76 48.16 92 4881 121740 110462586
Emotional distress 145.93 48.16 60 4913 44787 110539539
Oedema peripheral 140.91 48.16 117 4856 328543 110255783
Skin discolouration 137.44 48.16 59 4914 48987 110535339
Anhedonia 135.33 48.16 43 4930 15385 110568941
Joint stiffness 125.63 48.16 61 4912 67182 110517144
Extremity contracture 124.79 48.16 26 4947 1735 110582591
Deformity 121.79 48.16 36 4937 10124 110574202
Peau d'orange 112.19 48.16 18 4955 272 110584054
Skin disorder 102.00 48.16 46 4927 42867 110541459
Erythema 99.06 48.16 91 4882 291356 110292970
Mobility decreased 92.28 48.16 80 4893 237342 110346984
Pain 90.80 48.16 157 4816 954798 109629528
Muscle contracture 86.56 48.16 21 4952 2787 110581539
Skin plaque 85.67 48.16 29 4944 12616 110571710
Muscle tightness 70.09 48.16 26 4947 14736 110569590
Pruritus 67.74 48.16 105 4868 581455 110002871
Magnetic resonance imaging head abnormal 67.32 48.16 18 4955 3517 110580809
Magnetic resonance imaging abnormal 60.77 48.16 17 4956 3928 110580398
Gait disturbance 58.25 48.16 67 4906 278141 110306185
Musculoskeletal stiffness 57.93 48.16 67 4906 279755 110304571
Anxiety 57.46 48.16 74 4899 345004 110239322
Drug ineffective 56.43 48.16 3 4970 1520537 109063789
Skin exfoliation 54.45 48.16 39 4934 87612 110496714
Pain of skin 52.47 48.16 23 4950 20006 110564320
Haemodialysis 51.84 48.16 22 4951 17697 110566629
Muscular weakness 50.58 48.16 59 4914 248409 110335917
Skin mass 49.22 48.16 18 4955 9798 110574528

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08CA03 VARIOUS
CONTRAST MEDIA
MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Paramagnetic contrast media
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA MoA N0000175862 Magnetic Resonance Contrast Activity
FDA EPC N0000180184 Paramagnetic Contrast Agent
CHEBI has role CHEBI:37335 MRI contrast agent

Related Drugs by ATC class:

V08CA Paramagnetic contrast media 10 drugs
gadobenic acidgadobutrolgadofosvesetgadopentetate dimegluminegadopiclenolgadoteric acidgadoteridolgadoversetamidegadoxetic acidmangafodipir

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Magnetic resonance imaging indication 113091000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04284 KEGG_DRUG
4020689 VUID
N0000148302 NUI
4020689 VANDF
CHEBI:31642 CHEBI
CHEMBL1200346 ChEMBL_ID
C064925 MESH_SUPPLEMENTAL_RECORD_UI
6636 INN_ID
DB00225 DRUGBANK_ID
84F6U3J2R6 UNII
41144 RXNORM
10205 MMSL
4771 MMSL
d04083 MMSL
004259 NDDF
354088005 SNOMEDCT_US
396067007 SNOMEDCT_US
C0082646 UMLSCUI
153921 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
OMNISCAN HUMAN PRESCRIPTION DRUG LABEL 1 0407-0690 INJECTION 287 mg INTRAVENOUS NDA 29 sections